The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
Status:
Completed
Trial end date:
2017-09-13
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the plasma pharmacokinetics of gefapixant (MK-7264) administered
to participants with varying degrees of renal insufficiency (RI) compared to healthy matched
controls; and to investigate the extent of MK-7264 removal by hemodialysis (HD) in
participants with end stage renal disease (ESRD), following administration of a single 50 mg
dose of gefapixant.